Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

PoMA

PharmaDeviceNews PoMA

Laminar Pharma’s LAM561 Phase 2b/3 glioblastoma trial has completed its final patient visit, moving the investigational therapy toward a pivotal overall survival readout expected in 2027. Representative image.

Pharma & Biotech

Alpheus Medical reports early LDH biomarker findings from 15-patient glioblastoma study

by Pallavi Madhiraju
October 27, 2026
0 Comments

Alpheus Medical reports LDH biomarker findings in 15 glioblastoma patients. The early signal could aid MRI interpretation but needs validation.

Read More

Latest news and features

Tremont AI partners with AstraZeneca to develop AI models for preclinical drug safety assessment
Array Skin Therapy opens first Houston clinic to expand narrowband UVB treatment access
Alpheus Medical reports early LDH biomarker findings from 15-patient glioblastoma study
Orphan Therapeutics Accelerator licenses OTXL-101 gene therapy to revive development for rare paediatric disease
AbbVie submits FDA application for etentamig after Phase 3 CERVINO success in multiple myeloma
Vincora secures FDA approval for NeXuS transcatheter chordal repair feasibility study in the US
Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?
Orbis names a new CEO after its $1.4bn billion Novo Nordisk deal, but can AI-designed macrocycles replace injections?
Stevanato Group and Aptar Pharma partner to accelerate prefilled syringe system selection for biologics
Can Avanzanite accelerate NHS access to rare disease medicines in the UK?
Enhertu cut breast cancer recurrence risk by 53% against T-DM1, but will lung toxicity affect its use?
Pfizer’s TALZENNA and XTANDI cut prostate cancer progression risk by 52%, but who benefits most?

POPULAR NEWS

Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.

Pharma & Biotech

Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab

October 24, 2026

Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.

Pharma & Biotech

Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study

October 24, 2026

Representative image of researchers examining Alzheimer’s disease biomarker data as NeuroSense evaluates PrimeC’s multi-target potential in a small exploratory study.

Pharma & Biotech

NeuroSense links PrimeC to Alzheimer’s biomarkers, but can three patients justify another trial?

June 26, 2026

Latest business and industry news

Fujifilm instax mini Evo 2 release date, price and features: What changes from the original camera?
Cowboy Space opens Big Iron Express launch services as 2028 orbital data-centre mission approaches
Ather Energy turns profitable as sales jump 63%, but capacity expansion raises stakes
Egypt weighs military support for Saudi Arabia as Houthi attacks raise regional risks
Tata Consumer sales rise 14% as growth brands overtake traditional tea momentum

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.